Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 330

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 8
Chunk 330
---
 (8,656,664
    )

    Other (expense) income:

    Change in fair value of warrant liability

    81,441

    8,328,937

    Other (expense) income, net

    (7,144,868
    )

    207,473

    Total other (expense) income, net

    (7,063,427
    )

    8,536,410

    Net loss
     
    $
    (15,038,536
    )
     
    $
    (120,254
    )

    Net loss per share, basic and diluted
     
    $
    (87.68
    )
     
    $
    (8.44
    )

    Weighted-average shares used to compute net loss per share, basic and diluted

    171,510

    14,246

See accompanying notes to the consolidated financial statements.

 F-5

REVELATION BIOSCIENCES, INC. 

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

    Series A Preferred Stock

    Common Stock

    Additional Paid-in

    Accumulated

    Total Stockholders’

    Shares

    Amount

    Shares

    Amount

    Capital

    Deficit

    Equity

    Balance as of December 31, 2022 (as previously reported)

    1

    $
    —

    77,375

    $
    77

    $
    26,399,224

    $
    (25,346,848
    )
     
    $
    1,052,453

    Retrospective application of reverse recapitalization

    —

    —

    (72,540
    )

    (72
    )

    72

    —

    —

    Reverse stock split fractional stock round up

    —

    —

    (23
    )

    —

    —

    —

    —

    Balance at December 31, 2022

    1

    $
    —

    4,812

    $
    5

    $
    26,399,296

    $
    (25,346,848
    )
     
    $
    1,052,453

    Redemption of Series A Preferred Stock

    (1
    )

    —

    —

    —

    —

    —

    —

    Issuance of common stock from the February 2023 Public Offering